CG
EVLO

Cutler Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Cutler Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,650
Closed -$9K – 6400
2021
Q3 		$9K Buy
+1,650
New +$327K ﹤0.01% 4078

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's EVLO Position: Q2 2022 in Review

Cutler Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 55 shares — an estimated $2.55K sold.

Cutler Group first reported a position in EVLO in Q3 2021 and held it in 3 quarters. The position peaked at $36K in Q4 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • Cutler Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 55 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $2.55K.
  • Cutler Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Cutler Group's Evelo Biosciences, Inc. Common Stock position peaked at $36K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.